4//SEC Filing
Kummeth Charles R. 4
Accession 0001062993-23-015315
CIK 0000842023other
Filed
Jul 24, 8:00 PM ET
Accepted
Jul 25, 5:27 PM ET
Size
27.2 KB
Accession
0001062993-23-015315
Insider Transaction Report
Form 4
BIO-TECHNE CorpTECH
Kummeth Charles R.
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2023-07-21$88.36/sh−80,000$7,069,024→ 1,258,766 total
Holdings
- 400(indirect: By Step-Son)
Common Stock
- 66,600
Stock Options (Right to Buy)
Exercise: $66.97Exp: 2027-08-05→ Common Stock (66,600 underlying) - 1,200,000
Stock Options (Right to Buy)
Exercise: $94.52Exp: 2029-08-15→ Common Stock (1,200,000 underlying) - 299,768
Stock Options (Right to Buy)
Exercise: $66.97Exp: 2027-08-05→ Common Stock (299,768 underlying) - 228,600
Stock Options (Right to Buy)
Exercise: $47.60Exp: 2026-08-07→ Common Stock (228,600 underlying) - 66,600
Stock Options (Right to Buy)
Exercise: $66.97Exp: 2027-08-05→ Common Stock (66,600 underlying) - 400(indirect: By Step-Daughter)
Common Stock
- 779,084
Stock Options (Right to Buy)
Exercise: $31.26Exp: 2024-08-09→ Common Stock (779,084 underlying) - 361,336
Stock Options (Right to Buy)
Exercise: $44.33Exp: 2025-08-08→ Common Stock (361,336 underlying) - 240,888
Stock Options (Right to Buy)
Exercise: $44.33Exp: 2025-08-08→ Common Stock (240,888 underlying) - 342,900
Stock Options (Right to Buy)
Exercise: $47.60Exp: 2026-08-07→ Common Stock (342,900 underlying) - 52,900
Restricted Stock Units
→ Common Stock (52,900 underlying) - 51,516
Restricted Stock Units
→ Common Stock (51,516 underlying) - 153,180
Stock Options (Right to Buy)
Exercise: $66.97Exp: 2027-08-05→ Common Stock (153,180 underlying) - 83,504
Stock Options (Right to Buy)
Exercise: $120.45Exp: 2028-08-06→ Common Stock (83,504 underlying) - 32,064
Restricted Stock Units
→ Common Stock (32,064 underlying) - 125,260
Stock Options (Right to Buy)
Exercise: $120.45Exp: 2028-08-06→ Common Stock (125,260 underlying)
Footnotes (14)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2022.
- [F10]Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
- [F11]Options to purchase 22,200 shares vest on each of 8/5/21, 8/5/22 and 8/5/23.
- [F12]Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- [F13]Options to purchase 20,876 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025.
- [F14]600,000 options vest in full or in part on 7/1/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator), and 600,000 options vest in full or in part on 7/1/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.00 to $88.95 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Includes (i) 11,448 shares of restricted stock for which the risk of forfeiture will lapse on August 5, 2023; and (ii) 14,248 shares of restricted stock for which the risk of forfeiture will lapse as to 7,128 shares on each of August 6, 2023 and August 6, 2024.
- [F4]Fully exercisable.
- [F5]Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- [F6]17,632 shares vest on each of 8/15/2023 and 8/15/2025, and 17,636 shares vest on 8/15/2024.
- [F7]Options to purchase 57,152 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 57,148 shares vest on each of 8/7/2022 and 8/7/2023.
- [F8]Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- [F9]Options to purchase 38,292 shares vest on 8/5/21 and options to purchase 38,296 shares vest on each of 8/5/22, 8/5/23 and 8/5/24.
Issuer
BIO-TECHNE Corp
CIK 0000842023
Entity typeother
Related Parties
1- filerCIK 0001534980
Filing Metadata
- Form type
- 4
- Filed
- Jul 24, 8:00 PM ET
- Accepted
- Jul 25, 5:27 PM ET
- Size
- 27.2 KB